Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Biochemistry

Background:

• Rheumatoid arthritis (RA) is associated with increased oxidative stress.
• Reactive oxygen metabolites (ROMs) are key markers of oxidative stress.
• Anti-tumour necrosis factor (TNF)-α therapy is a treatment for active RA.

Purpose of the Study:

• To evaluate circulating ROM levels in active RA patients before and during anti-TNF-α therapy.
• To assess the impact of anti-TNF-α therapy on oxidative stress markers in RA.

Main Methods:

• 40 patients with active RA received subcutaneous anti-TNF-α for 52 weeks.
• Circulating hydrogen peroxide, a marker of oxidative stress, was quantified.
• Measurements were taken at baseline, 24 weeks, and 52 weeks.

Main Results:

• Circulating ROM levels significantly decreased after 24 and 52 weeks of anti-TNF-α treatment compared to baseline.
• A significant direct correlation was observed between disease activity score and ROM levels.
• The study included 40 patients, with ROM levels measured in mgH2O2/dl.

Conclusions:

• Anti-TNF-α therapy effectively controls disease activity in RA patients.
• TNF-α inhibition leads to a reduction in circulating reactive oxygen species.
• This suggests a role for anti-TNF-α therapy in mitigating oxidative stress in RA.